Astria Therapeutics (ATXS) Net Income towards Common Stockholders: 2017-2018
Historic Net Income towards Common Stockholders for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to -$5.9 million.
- Astria Therapeutics' Net Income towards Common Stockholders fell 6.65% to -$5.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$26.0 million, marking a year-over-year increase of 5.05%. This contributed to the annual value of -$26.0 million for FY2018, which is 4.93% up from last year.
- Astria Therapeutics' Net Income towards Common Stockholders amounted to -$5.9 million in Q4 2018, which was down 1.27% from -$5.8 million recorded in Q3 2018.
- In the past 5 years, Astria Therapeutics' Net Income towards Common Stockholders registered a high of -$5.5 million during Q4 2017, and its lowest value of -$7.9 million during Q1 2017.
- For the 2-year period, Astria Therapeutics' Net Income towards Common Stockholders averaged around -$6.7 million, with its median value being -$6.8 million (2017).
- The largest annual percentage gain for Astria Therapeutics' Net Income towards Common Stockholders in the last 5 years was 16.70% (2018), contrasted with its biggest fall of 6.65% (2018).
- Astria Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$5.5 million in 2017, then dropped by 6.65% to -$5.9 million in 2018.
- Its Net Income towards Common Stockholders stands at -$5.9 million for Q4 2018, versus -$5.8 million for Q3 2018 and -$6.6 million for Q2 2018.